There is evidence that some elderly patients with chronic schizophrenia experience marked impairments in cognitive functioning. Assessment of these patients may be difficult with traditional neuropsychological measures. The purpose of the present study was to determine if cognitive functioning could be validly assessed with the Alzheimer's Disease Assessment Scale-Late Version Cognitive factor score (ADAS-L Cog) in patients whose scores on the Mini-Mental State Examination (MMSE) reflect profound cognitive impairment. Patients with MMSE scores from 0 to 10 were selected from a larger database. Neuropsychological instruments designed for the assessment of mild to moderate dementia were found to be inadequate in this profoundly impaired population, due to floor effects. In contrast, there was a significant relationship between ADAS-L scores and several criterion measures, including the MMSE (R = −.71, P < .001), the Social Adaptive Functions Evaluation (SAFE) social functions scale (R = .47, P < .001), and the negative symptom total score of the Positive and Negative Syndrome Scale (PANSS) (R = .412, P < .001). The MMSE was somewhat less strongly correlated with both social functions (R = −.401, P < .001) and the negative symptom total score of the PANSS (R = −.366, P < .001). These results suggest that cognition can be reliably and validly assessed with instruments such as the ADAS-L that are designed for the assessment of severely impaired patients.
Introduction
Cognitive deficits are common in schizophrenia (Gold & Harvey, 1993) and cognitive functioning is a major predictor of functional outcome in patients with schizophrenia (Green, 1996) . While ambulatory patients with schizophrenia manifest little evidence of deterioration in cognitive functioning in later life (Eyler Zorilla et al., 2000; Heaton et al., 1994) , older patients with a chronic course of illness and severe lifelong functional deficits often manifest much more significant impairments in their cognitive functioning (Arnold & Trojanowski, 1996; Davidson et al., 1995) . Though the number of hospitalized patients with schizophrenia is lower than at any time in the past, there are hundreds of thousands of residents of nursing home care who have a lifelong diagnosis of schizophrenia (Goldman, Feder, & Scanlon, 1986) and studies of different samples of these patients have found that they routinely have severe cognitive deficits (Bartels, Mueser, & Miles, 1997a; Harvey et al., 1998) . The severity of these deficits renders cognitive assessment difficult, as many patients may be functioning at levels that would be consistent with a floor effect on traditional neuropsychological tests. Alternative assessment strategies may be required for these patients.
Schizophrenic patients with Mini-Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975) scores consistent with moderate (MMSE < 23) to severe dementia (MMSE < 18) have proven to be testable on traditional and abbreviated neuropsychological assessment batteries. For instance, Harvey, Mohs, and Davidson (1993) examined 72 patients with chronic unremitting schizophrenia, including 24 who had experienced a leucotomy, on an extended neuropsychological battery. Although performance was very poor, all patients were testable. Abbreviated neuropsychological assessments have been employed with patients whose MMSE scores were lower than 17. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) battery is a brief neuropsychological evaluation developed for the diagnosis and staging of Alzheimer's Disease (AD; Morris et al., 1989) . As such, it was designed for use in mild to moderately severe dementia. Previous research with this battery has demonstrated that the stage of illness of AD patients can be reliably ascertained with this battery (Welsh, Butters, Hughes, Mohs, & Heyman, 1991 , 1992 and that AD patients can be discriminated from patients with schizophrenia in the range of MMSE score of 10-17 on a cross-sectional basis (Davidson et al., 1996) . In this study, however, patients with MMSE scores of less than 10 were excluded from the analyses of the data.
In order to address the problem of assessment of severely impaired patients with dementia, neuropsychological batteries have been designed to measure cognition in severely impaired patients, who may not be testable with standard batteries. Panisset, Roudier, Saxton, and Boller (1994) found the Severe Impairment Battery (SIB) to be a reliable and valid tool for measuring cognition in severely to profoundly demented patients with probable AD. In this study, patients with MMSE scores of 0 to 11 could be separated into two groups (0-5 and 6-11) with the SIB. The Alzheimer's Disease Assessment Scale-Late Version (ADAS-L; Mohs, 1989 ) is an abbreviated assessment battery designed to measure the components of more advanced dementia than its predecessor, the ADAS (Rosen, Mohs, & Davis, 1984) . Kincaid et al. (1995) found the ADAS-L to be a valid instrument for rating cognitive and behavioral impairment in severely impaired elderly patients with schizophrenia. In this study, scores on the scale accurately stratified severely impaired patients with schizophrenia, with Clinical Dementia Rating score as the criterion measure. Furthermore, the ADAS-L was superior to the MMSE in the classification of more severe levels of impairment, including accurate discrimination of patients with CDR scores of 2.0 (moderate), 3.0 (severe), and 4.0 (extreme).
The present study sought to determine if cognitive impairment can be reliably and validly assessed in patients with schizophrenia whose scores on the MMSE indicate profound impairment. Additionally, the present study sought to determine if components of the more comprehensive assessment previously used to assess both AD and schizophrenia, the CERAD battery (naming, category and verbal fluency, praxis, and verbal learning and recall), are useful in schizophrenic patients who scored 10 or less on the MMSE. If these more traditional neuropsychological instruments show floor effects, making them inadequate measures of cognition in profoundly impaired patients with schizophrenia, it is important to search for alternative measures. Thus, the concurrent validity of the cognitive portion of the ADAS-L (ADAS-L Cog) and the MMSE was determined to assess the feasibility of evaluating cognition in this population. Reliability analyses of the MMSE and ADAS-L Cog were performed to determine internal consistency of the measures. In addition, the criterion-related validity of the ADAS-L Cog and the MMSE was examined, by correlating performance on these two measures with typical correlates of cognitive deficits in schizophrenia, including social functions and negative symptoms.
Method

Participants
Participants were selected from a sample of over 1400 geriatric patients with schizophrenia who at the time of evaluation resided at either a state or VA psychiatric hospital or a nursing home. All nursing home patients had at least 10 consecutive years of inpatient psychiatric hospitalization prior to being referred to a nursing home. Inclusion criteria for the present study were a diagnosis of schizophrenia or schizoaffective disorder, an MMSE score between 0 and 10, a CDR (Hughes, Berg, Danziger, Cobin, & Martin, 1982) overall score of two or greater, indicating at least moderately severe dementia, and an ADAS-L Cog score of less than 35, indicating that on this test the patient correctly answered at least one question. Exclusion criteria for the present study included a comorbid Axis I disorder and uncooperativeness with any part of the evaluation. Additionally, in order to exclude patients with newly incident dementing conditions, any patient who a neurologist determined on the basis of a scheduled annual clinical evaluation had experienced "rapid cognitive decline" in the past year, were also excluded.
Patient subjects in this study were older patients with lifelong schizophrenia. These subjects were participants in a longitudinal study of symptomatic, cognitive, and adaptive aspects of late-life schizophrenia. Data for these patients came from the databases of the Mt. Sinai Mental Health Clinical Research Center and the VA VISN 3 MIRECC. The schizophrenic patients had been diagnosed with a previously published procedure . All patients received a lifetime chart review, supplemented by direct interviews with the patients and interviews with their patient care staff. Patients were required to meet diagnostic criteria for schizophrenia for each decade of their life after their first psychiatric contact. Patients were excluded from the overall research database because of diagnoses that ruled out schizophrenia, including affective disorders. In addition, patients with a history of head trauma with loss of consciousness, rapid cognitive decline detected by a neurologist at an annual examination (see above), seizure disorders, substance dependence, or cerebrovascular accidents, were also excluded. From the larger database, 948 patients had a diagnosis of schizophrenia or schizoaffective disorder, met all other inclusion criteria, and were administered and cooperated with all of the measurements selected for analyses in the present study. Of these patients, 164 scored between 0 and 10 on the MMSE. From these 164 patients, 64 had ADAS-L Cog scores of 35, meaning they did not answer any questions correctly on either the ADAS-L Cog or the MMSE. These 64 patients were excluded from all further analyses. Thus, 100 patients (69 inpatients, 31 nursing home residents; 58 male, 42 female) met inclusion criteria. See Table 1 for subjects' demographic information and the distributions of the MMSE scores of the group.
Clinical assessments
All patients were rated for clinical symptomatology with the Positive and Negative Syndrome Scale (PANSS; Kay, 1991) . This is a 30-item scale with 7 items measuring positive symptoms, 7 items measuring negative symptoms, and 16 items measuring general aspects of psychopathology. The total scores on positive and negative subscales are used as the dependent measures. Interrater reliability of these ratings in our patients was previously found to be acceptably high, with intraclass correlations (n = 30) ranging from a low of .86 to a high of 1.00 (all P 's < .001).
CERAD cognitive battery
Word list learning and delayed recall
A 10-item list of words was presented to the subject on three separate learning trials. After each trial, free recall of the list was required of the subjects. After a delay, filled by the Praxis Drawings described below, a delayed recall of the word list was required. The dependent variables are the total number of words correctly recalled over the three learning trials and the number of words recalled at the delayed recall.
Praxic drawings
Four drawings (circle, diamond, overlapping rectangles, cube) were presented to the subject, who was instructed to copy them exactly. Reproductions were scored according to predetermined criteria and the dependent measure is the total score for the four drawings.
Modified Boston Naming Test
Subjects were presented with 15 line drawings and asked to name the object depicted. The drawings consisted of five objects with high frequency of occurrence in spoken English, five of moderate frequency, and five of low frequency. The dependent variable is the total number of correct responses.
Category fluency
Subjects were instructed to name as many different animals as possible in one minute. The dependent variable is the number of unique animals named.
An additional assessment was performed in order to obtain an estimate of premorbid functioning. The Wide-Range Achievement Test-Revised (WRAT-R; Jastrak, 1984) word recognition reading subtest was administered as a measure of putative premorbid academic competence. The dependent measure is the total score.
Alzheimer's Disease Assessment Scale-Late Version
This test provides a direct assessment of the patients' cognitive abilities through tests of memory, language, praxis, and orientation, as well as six clinician-rated items measuring impressions of the patient's cognitive impairment and psychiatric symptoms. Additionally, the ADAS-L has four items rated by the examiner based on a caregiver interview to assess cognition and inter-personal skills. A final four items rated impairment in activities of daily living (ADLs) based on caretaker interview. Thus, the evaluation is divided into four sections, with errors receiving various point scores, and yields a total score ranging from 0 (no impairment) to 81 (maximum impairment).
The ADAS-L Cog yields error scores ranging from 0 to 35. It includes six subtests: (1) immediate recall of three words presented over three trials for a score of 0-9; (2) remote memory, with two points for each error in producing the year born, producing the first president, producing two other presidents, and producing the letter that comes after A, B, C (0-6); (3) orientation, which requires the patient to say his or her full name, age, the month, the current year, the country, and the name of the place of assessment for one point each (0-6); (4) naming, which requires the patient to identify toy versions of six 3-D objects for one point each (0-6); (5) commands, which requires the patient to make a fist, point to the floor, and put their hands together, then pull them apart for one point each (0-3); (6) expressive language, which requires the patient to make a statement that begins with "I wish. . . " and is scored from 0 to 3.
Social Adaptive Functioning Evaluation (SAFE) scale
This 17-item scale was developed by the current investigators and measures social-interpersonal, instrumental, and impulse-control deficits. This scale was designed to rate geriatric patients living in an inpatient facility after observation of and interaction with the subject, as well as a caregiver interview and chart review. Previous research with this scale found that both social and instrumental skills deficits were related to cognitive impairments, while deficits on the impulse control subscale were not (Harvey, Sukhodolsky, Parrella, White, & Davidson, 1997) . This scale has suitable reliability, with interrater reliabilities of the items all exceeding .88 (ICC, n = 60). The total score is used as the primary dependent measure; measures of self-care ability, social functioning, and impulse control are also derived through previously validated subscales of the measure.
Results
CERAD neuropsychology battery
Descriptive statistics for the CERAD battery tests are displayed in Table 2 . Over 50% of patients scored zero on all tests except for the Boston Naming Test, on which 33% scored zero. Additionally, means and standard deviations were extremely low for these tests (see Table 2 CERAD battery scores and outcome measures for patients with MMSE scores of 0-10 Table 2 ). Despite previous publications suggesting that less impaired (mean MMSE = 20.37) elderly patients with chronic schizophrenia do not demonstrate marked deficits on the WRAT-R (Harvey et al., 2000) , the scores obtained on the WRAT-R by this group were very low on average and are inconsistent with the levels of education obtained by this sample of subjects.
Reliability analysis
The ADAS-L Cog subtests showed a wider range of scores than the MMSE subtests and manifested less evidence of floor effects (see Tables 3 and 4) . Pearson correlation coefficients found the ADAS-L Cog total score to be correlated with all of the individual subtest scores (all P < .01) The correlations of the subtests with the total score are as follows: recall (r = .84), remote memory (r = .68), orientation (r = .47), naming (r = .57), commands (r = .63), and expressive language (r = .59). Additionally, most of the subtests were significantly intercorrelated. The MMSE domains had relatively smaller correlations with the MMSE total score (range r = .11-.82), with the correlations between the attention and recall domains and the total scores not reaching statistical significance.
The internal consistency (coefficient alpha) of the ADAS-L subtests was .64, while for the MMSE domains it was .42. These data again indicate that in patients selected for very low MMSE scores, the ADAS-L cognitive subscale is somewhat more reliable. Higher scores indicate more errors on the ADAS-L. 
Concurrent validity
Pearson correlation coefficients found convergence between total scores on the MMSE and the ADAS-L Cog in the present population with 50% of the variance in common (r = −.71, P < .001), despite the fact that the patients were selected for performing very poorly on the MMSE. As shown in Figure 1 , this relationship is remarkably linear and even extends to patients whose MMSE score was 0. These patients performed the ADAS-L Cog more poorly than patients with MMSE scores of 1, t (11) = 3.37, P = .006 (see Fig. 1 ).
Criterion-related validity
Pearson correlation coefficients were performed to examine relationships between cognition and social adaptive functioning and symptomatology. The total score on the ADAS-L Cog was correlated with the social functions scale of the SAFE (r = .47, P < .001), the SAFE total scale score (r = .32, P = .001) and the negative symptom total score on the PANNS (r = .41, P < .001). The ADAS-L Cog was not significantly correlated with the instrumental and self-care scale of the SAFE (r = .081, P = .424) or the ADAS-L ADLs scale (r = .15, P = .128). The ADAS-L Cog was not significantly correlated with the PANSS positive symptom total score (r = −.08, P = .41) or the General Psychopathology total score (r = .10, P = .321).
The MMSE total score was also correlated, though to a slightly less degree than the ADAS-L Cog, with the social functions scale of the SAFE (r = −.40, P = .002), the SAFE total scale score (r = −.31, P < .001), and the negative symptom total score (r = −.37, P < .001). Additionally, the MMSE was correlated with the ADAS-L ADLs scale (r = −.22, P = .03). The MMSE was not significantly correlated with the instrumental and self-care scale of the SAFE (r = −.19, P = .12) or the PANSS positive symptom total score (r = .00, P = .99) or the General Psychopathology total score (r = −.09, P = .38).
Linear regression analyses were conducted to find predictors of outcome variables. The MMSE and ADAS-L Cog total scores were examined as predictor variables for social adaptive functioning and symptomatology. Simultaneous regression analyses were first used to determine if there were significant relationships between cognitive functioning (MMSE and ADAS-L Cog scores) and outcome variables. If simultaneous regression yielded significant results, the variables were reexamined in a forward entry stepwise regression analysis to determine which variables accounted for a significant portion of the variance.
Cognitive functioning was found overall to be a significant predictor of the SAFE total score [F (2, 97) = 6.41, P = .002, R 2 = .12]. Forward entry stepwise regression analysis found that the ADAS-L Cog was a significant predictor of SAFE total score [F (2, 97) = 11. 
Discussion
The results of this study indicate that standard neuropsychological tests used to examine patients with AD and schizophrenia with mild to moderate dementia such as the Boston Naming Test, category fluency, praxic drawings, and word list learning and recall as part of the CERAD battery were not adequate to evaluate cognition in a particularly low functioning population. Only the modified Boston Naming Test had fewer than 50% of patients with a total score of 0 on the test. In contrast, the cognitive functioning subscale of the ADAS-L was much more likely to generate valid scores in this population. The MMSE and the ADAS-L Cog were found to be highly correlated in these patients. In fact, some patients who received a score of 0 on the MMSE were still able to perform the ADAS-L Cog in a manner consistent with valid scores, as evidenced by performing systematically more poorly than patients with MMSE scores of 1. Thus, some proportion of patients with schizophrenia who appeared untestable on the MMSE actually had evidence of cognitive functioning that could be measured with tests aimed at lower functioning patients. While the ADAS-L Cog showed reasonably good internal consistency, many of the MMSE domains did not correlate with each other in these low functioning patients. The ADAS-L Cog, designed to examine patients with very low levels of cognitive functioning, proved to be a better correlate than the MMSE of several different domains of outcome in particularly low functioning patients.
These data provide some information about differential preservation and loss of functioning in low functioning patients with schizophrenia. Specifically, confrontation naming was the most preserved skill, across the MMSE, the ADAS-L, and the CERAD battery. Using the simple items on the ADAS-L Cog, the mean score was approximately 50% correct, with only 14% of the patients failing all items. Thus, even in very low functioning patients there is evidence of preservation of specific verbal skills. Responding to commands was also consistent with this level of performance. In contrast, attention and delayed recall were most impaired across all three domains of assessment. As a result, very low functioning patients with schizophrenia have evidence of very little in way of preserved memory functions. These data may serve to guide later neuropathological studies of patients with schizophrenia, since many patients who are subjects in longitudinal postmortem research in schizophrenia have had very low levels of cognitive functioning similar to the current patients .
There are several limitations of the current study. First is that the patients were selected for being particularly low functioning and these results are not suggested to be relevant to higher functioning patients who would be likely to obtain ceiling effects on the ADAS-L Cog. Since the MMSE was the factor by which the low functioning patients were selected, the reliability of the scores was likely to be reduced through truncation of the range of scores. In addition, although we were able to obtain valid ADAS-L Cog scores on some patients with MMSE scores of 0, there were still more patients on whom neither the MMSE nor the ADAS-L cognitive subscales were validly performed. We also saw suppression of the scores on the PANSS and the SAFE scale by selection of low functioning patients, which was likely to have affected the levels of correlation between cognitive performance and the outcome measures. Medication status was not considered in the analyses. Newer antipsychotic medications have shown superior effects on cognitive functioning than conventional antipsychotic medications (Harvey & Keefe, 2001; Keefe, Silva, Perkins, & Lieberman, 1999) . At this time, however, there are no data available on whether these cognitive enhancement effects occur in patients at this low level of cognitive functioning and the levels of cognitive improvement previously reported would not have improved these patients' functioning notably. Undetected vascular pathology or AD could be present in these patients, although our previous research has suggested that these conditions are not extremely common (Powchik et al., 1998; Purohit et al., 1998) . Not all patients with schizophrenia would be expected to ever manifest such low levels of functioning. Yet, studies from several different research groups have suggested that identification of chronic schizophrenic patients with very low scores on the MMSE is quite common in hospital (Arnold & Trojanowski, 1996; Davidson et al., 1995) , nursing home (Bartels et al., 1997a) , and community settings (Bartels, Mueser, & Miles, 1997b) .
A final issue is that of additional comorbidities or other factors that could artifactually reduce scores on the ADAS-L Cog. It is not likely that substance abuse is a major comorbid factor in patients with a history of living in institutions for their whole lives. Empirically, AD and vascular dementia are not the sole causes of these impairments . Lifelong low functioning consistent with MMSE scores under 10 is not a viable explanation, since some of the patients in the sample had completed college. Our findings of significant correlations between performance-based measures, such as the ADAS-L Cog, and observationally rated scales such as the SAFE scale argue against poor motivation as a cause of the poor performance. Undetected medical problems may be an additional potential confound. In a longitudinal study of 124 institutionalized patients followed for 48 months, neither baseline severity of physical illness nor newly incident physical illness predicted cognitive or functional decline (Friedman et al., in preparation) . While the subjects in that study were higher functioning than the current sample, it is still likely that physical illness is not the sole factor producing low scores on these measures.
While it may be argued that these results are not broadly applicable to patients with schizophrenia, of a total sample of 948 institutionalized patients without additional comorbidities, 17% had MMSE scores under 11. Although the majority of older patients with schizophrenia are not treated in institutions, the large number of patients that we have seen in this research program has indicated that there are likely to be many other patients with schizophrenia treated at nursing homes or in other institutions who are not seen at academic centers. Since close to one fifth of these patients may be very low functioning, based on our data, valid assessment of these patients may be an important clinical priority. Cognitive impairment, even at very low levels of functioning, was a valid predictor of social and adaptive functioning outcomes. These results broaden the implications of previous studies that suggested that functional and cognitive deficits were strongly correlated in good outcome patients, both older and younger (Green, 1996) . Even at levels of cognitive functioning consistent with single-digit scores on the MMSE, functional deficit is predicted by performance on cognitive tests. Cognitive impairment, as measured on the MMSE and the ADAS-L Cog, was related to higher negative symptomatology as well. Studies of less impaired patients have consistently found that cognitive deficits are similarly related to the severity of negative symptomatology (Addington, Addington, & Maticka-Tyndale, 1991; Davidson et al., 1995) . The present study did not find a significant relationship between positive symptomatology and cognition, in accordance with other studies of less impaired patients.
Valid assessment of severely impaired patients with schizophrenia is possible and has implications for treatment research. Recently, a number of medications have been approved to treat cognitive impairment in AD. If medications are to be used to treat cognitive impairment in schizophrenia, measurement and tracking of cognitive status, even in very low functioning patients, are essential to measure their efficacy. Since the results of the present study demonstrate that the ADAS-L Cog is a reliable and valid measure for this population, it may be useful as an outcome variable in this type of research.
